Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
3 hedge funds and large institutions have $2.56M invested in Seelos Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
66% less capital invested
Capital invested by funds: $7.61M → $2.56M (-$5.05M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$468K |
| 2 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$149K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$23K |
| 4 |
Bank of New York Mellon
New York
|
-$21K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GC
26
Guggenheim Capital
Chicago,
Illinois
| – | -$10K | – | – |
|
|
HVC
27
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| – | -$149K | – | – |
|
|
MBA
28
McQueen Ball & Associates
Bethlehem,
Pennsylvania
| – | -$8K | – | – |
|
|
29
Northern Trust
Chicago,
Illinois
| – | -$23K | – | – |
|
30
State Street
Boston,
Massachusetts
| – | -$4K | – | – |
|
31
UBS Group
Zurich,
Switzerland
| – | -$1K | – | – |
|
SEEL Hedge Fund Activity: Q4 2016 in Review
3 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2016, worth a combined $2.56M — down 66% from $7.61M a quarter earlier.
Fund positioning in SEEL was balanced in Q4 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Anson Funds Management, cutting an estimated $468K.
- 3 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $2.56M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2016, down 66% quarter-over-quarter.
- 0 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2016 and 0 closed out.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2016 was Anson Funds Management, an estimated $468K sold.
Based on aggregated 13F filings for Q4 2016.